FIND2CURE
FIND2CURE
We recognize the importance of conducting biomarker-guided studies in a timely and efficient manner. Our ground-breaking strategy includes on-site personnel, proactive eligibility screening, and access to a network of trial-ready sites with a wide population of pre-screened patients. We provide data and resources through our precision trials programme to facilitate rapid enrollment of registration-enabling trials for new approvals and indication expansion.
Our genomics discovery platform makes use of large-scale clinical-molecular data sets created in the course of routine genomic clinical trials. This proprietary resource fuels our ability to discover new molecular-treatment connections and allows us to create data-driven Gene-Drug products that improve patient treatment plan outcomes.
The F2C Network is made up of clinical trial sites with a wide population of advanced cancer patients data sets that have been molecularly profiled and will drug match efficiently.
Biomarker frequency estimates, site selection, and topic eligibility evaluations are all based on a comprehensive clinical molecular database sets obtained from our own in-house build efficient pipelines.
F2C offers a data-driven approach to gaining approval for new and expanded precision drugs. Our strategy, which includes links to a network of trial-ready sites that are standardized on our molecular profiling and data platform, allows us to test novel molecular-treatment hypotheses quickly. To guide biomarker selection and trial design, we use real-world data to gain insights into patient populations and the efficacy of current therapies. This method ensures that patients are quickly and efficiently enrolled in biomarker-guided clinical trials.
COMPREHENSIVE GENOMIC PROFILING
F2C-NGS is a robust genomic profiling test that performs exceptionally well on small tumour tissue samples on co-isolated RNA and DNA, the F2C-gene assay is performed. SNVs, short insertions and deletions (indels), copy number alterations (CNAs; amplifications and deep deletions), microsatellite instability (MSI) status, gene fusions, and tumor mutation burden (TMB) are all evaluated at the same time.
Find out more >
GENE EXPRESSION PROFILING
F2C Expression is an investigational test that uses DNA and RNA-seq to analyse 50+ emerging oncogene panels, providing a more comprehensive picture of the tumor and its microenvironment and can all be incorporated into predictive biomarkers using our innovative assay and computational methods.
For more details, please contact us >Practice regulations.
